Contents
In the Medtronic SubQ stimulation settlement, Medtronic agreed to pay $2.8 million to resolve allegations that it promoted an investigational stimulation procedure and caused false claims to Medicare and TRICARE. The complaint described off-label promotion that reached beyond teaching physicians where to place the leads. The whistleblower’s complaint described representatives teaching doctors how to bill the procedure and selling them on the profit from adding it to another implant.
The Justice Department announced the civil settlement on February 6, 2015. It alleged that Medtronic knowingly caused dozens of physicians in more than 20 states to submit claims for nonreimbursable SubQ procedures from 2007 through 2011. A former Medtronic sales representative brought the False Claims Act qui tam case.
SubQ stimulation placed leads just beneath the skin near an area of pain, usually the lower back, to create a tingling sensation intended to relieve chronic pain. The government alleged that Medtronic promoted that use of its spinal cord stimulation medical devices even though the safety and effectiveness of SubQ had not been established as required by the Food and Drug Administration.
The whistleblower’s complaint explains the physical difference. Traditional spinal cord stimulation placed electrode-bearing leads in the epidural region of the spine. Traditional peripheral nerve stimulation put electrodes around, or in direct contact with, a major peripheral nerve. SubQ placed them under the skin to stimulate a broad field of tiny nerve fibers near the painful area.
The complaint also called the procedure peripheral nerve field stimulation or subcutaneous targeted neurostimulation.
That distinction ran through the product paperwork. The whistleblower alleged that Medtronic’s labeling described traditional spinal cord and peripheral nerve stimulation, while its patent applications described SubQ as a new use. The complaint challenged the promotion of that new procedure with medical devices whose labeling still described the old ones.
The government’s position was that Medtronic’s authorization to market spinal cord stimulation medical devices did not make the new SubQ procedure reimbursable.
Medtronic’s alleged training program taught the procedure and the billing together. The Justice Department said the company arranged for physician-customers to attend Medtronic-sponsored on-site programs about using its spinal cord stimulation medical devices for SubQ stimulation.
The complaint gives that account a view from inside the sales team. The former representative alleged that, after transferring to the Austin territory, he watched a colleague instruct a physician to bill SubQ leads as peripheral nerve lead placements using CPT 64555. On subsequent sales calls, the same colleague allegedly repeated the instruction. The whistleblower said he then saw physicians implant and bill the leads as instructed.
The pitch joined the code to the physician’s earnings:
[The sales representative] explained to the physicians that they could combine the Sub-Q implants with their epidural implants and make upwards of $10,000 profit on each patient, while adding only minutes to the procedure time.
Whistleblower’s allegation, United States ex rel. Nickell v. Medtronic Inc., complaint, paragraph 27
The same conversation supplied the procedure, the billing description and the reason to do more of it.
When coding questions arose, the complaint alleged, a Medtronic reimbursement specialist met with physicians or hospital personnel to explain the company’s recommended billing procedures. The alleged advice also reached ambulatory surgery centers and hospital outpatient centers where patients received permanent implants.
The training spread through the sales force as well. The whistleblower alleged that he trained other representatives in SubQ implantation techniques, coding and billing, and that Medtronic sent him to train another sales team. He also alleged that Medtronic paid a physician to let visiting pain physicians observe SubQ procedures.
The complaint’s coding allegation was concrete: physicians described SubQ as traditional peripheral nerve stimulation when seeking payment. The distinction between direct stimulation of a selected nerve and stimulation of a field beneath the skin disappeared from the bill.
The whistleblower alleged that an unlisted-procedure code would have alerted Medicare to make a separate coverage decision. Using the traditional peripheral nerve code instead allegedly presented the new procedure as one for which Medicare had already made that decision.
The training mattered because the manufacturer allegedly supplied that description.
The complaint alleged that the physician’s financial incentive extended beyond the fee for placing a lead. Medtronic allegedly marketed the difference between what a pain physician paid for trial leads and what the physician could bill Medicare for them. The trial then opened the way to a permanent implant at a surgery center or hospital outpatient center.
The whistleblower’s account described two payment paths. In an office trial, the physician bought the temporary lead arrays and billed for them. For a permanent implant, the surgery center bought the leads, and their cost was bundled with other equipment and services in the facility’s payment. The alleged incentive started with the office purchase and continued into the referral for the larger procedure.
The complaint identified L8680 as the medical device code used for trial leads in the physician’s office. It alleged that Medtronic encouraged physicians to bill separately for every electrode contact on an array:
Medtronic advises pain doctors that they can bill this code for each electrode contact on an eight-contact lead array, producing a selling price to Medicare of $3,192 per trial lead array.
Whistleblower’s allegation, United States ex rel. Nickell v. Medtronic Inc., complaint, paragraph 102
In the same passage, the whistleblower alleged that Medtronic’s rebates and discounts frequently reduced the physician’s cost to $700 or less per array. That was the alleged attraction: a substantial margin on the hardware in addition to the professional fee for putting it in.
The complaint alleged that Medtronic used those low prices and discounts to induce pain physicians to refer patients for permanent SubQ and spinal cord stimulation implants. The physician who conducted the trial influenced the next purchase, even though the surgery center would buy the permanent equipment.
The physician can strongly influence medical device selection while the institution buys the product and receives payment for the procedure. For an implanted medical device, Medicare commonly includes the equipment’s cost in the procedure or facility payment.
The whistleblower also alleged that Medtronic promoted SubQ in combination with traditional spinal cord stimulation at both the trial and permanent implantation stages. The complaint described adding SubQ leads to spinal cord stimulation leads, then implanting separate pulse generators for the combined treatment.
The complaint challenged the clinical reasoning behind testing both procedures together. If a patient received both at once, the trial would not isolate which procedure produced the benefit. The whistleblower alleged that the combined approach generated claims for medically unnecessary care and for a combination that was itself experimental.
The sales proposition was more hardware and another procedure. The allegation was that federal health care programs were asked to fund that expansion before the combined treatment’s benefit had been established.
The Justice Department described Medtronic’s settlement as resolving allegations that the company caused claims for nonreimbursable SubQ procedures. Its announcement centered on the investigational use, the physician training and the resulting Medicare and TRICARE claims.
The former sales representative was awarded a 22% whistleblower share of the recovery. He brought knowledge from inside the neuromodulation sales operation, including the instructions given during sales calls and the training of other representatives.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
The SubQ complaint put sales, clinical training and reimbursement support in the same account. The representative knew what physicians were being taught to perform, what the company recommended they bill, and how the profit was presented. The reimbursement specialist dealt with questions from the people submitting the claims. Each role saw a different part of the same sale.
The complaint also alleged that concerns reached management. A manager questioned the legitimacy of SubQ and whether Medicare would stop reimbursement, and reportedly said a regional vice president shared the concern. In the whistleblower’s account, doubts about reimbursement went up the management chain, and sales quotas went up anyway.
Manufacturer billing advice appears in other medical device fraud cases. In a separate settlement announced on February 5, 2015, ev3, formerly Fox Hollow Technologies, agreed to pay $1.25 million over allegations that it induced hospitals to claim unnecessary inpatient admissions for minimally invasive atherectomy. The disputed claim concerned the hospital admission rather than the placement of a stimulation lead.
In its September 6, 2024 announcement concerning THD America, the Justice Department described a $700,000 settlement over allegations that the company encouraged additional or substitute procedure codes to avoid denials associated with a temporary code. The recurring issue is the manufacturer’s role in shaping the provider’s request for payment.
For someone who knows the sales operation, the connection may be visible before the claim reaches a payer. A training session can explain the implant technique while the accompanying billing advice tells the office how to describe it. In SubQ, the whistleblower’s account connected those instructions to the procedures and bills he said he witnessed.
If you saw a medical device company’s training pair a procedure with billing instructions that concealed what physicians actually performed, tell our whistleblower experts what happened. We work beside you to build your strongest medical device whistleblower case, from the first conversation through its pursuit. We bring in medical device fraud whistleblower lawyers who understand manufacturer promotion and reimbursement.